Skip to main content
Clinical Trials/NCT05558865
NCT05558865
Completed
Not Applicable

Evaluating the Effectiveness of a Digital Therapeutic (Somnovia) for People With Insomnia Disorder - a Randomized Controlled Trial

Gaia AG1 site in 1 country290 target enrollmentNovember 8, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Insomnia Disorder
Sponsor
Gaia AG
Enrollment
290
Locations
1
Primary Endpoint
Insomnia Severity Index (ISI)
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The trial aims to evaluate the effectiveness of a novel digital health application (somnovia), which was designed to increase sleep quality in persons with insomnia disorder. Therefore, 290 people with insomnia disorder will be recruited and randomized to two groups: (1) a control group, in which they may engage with any treatment for insomnia disorder and are offered access to somnovia after a delay of 6 months (i.e., Care-as-Usual [CAU]), or (2) to a treatment group that immediately receives 6-month access to somnovia and may also use CAU. The primary outcome measure is the score of the Insomnia Severity Index (ISI), collected at three months post-baseline.

Registry
clinicaltrials.gov
Start Date
November 8, 2022
End Date
September 18, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Gaia AG
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • diagnosis of chronic insomnia
  • impaired quality of sleep (Insomnia Severity Index Score ≥ 10)

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Insomnia Severity Index (ISI)

Time Frame: 3 months after randomization

The ISI is a 7-item patient-reported outcome measure (PROM) assessing the nature, severity, and impact of insomnia on a 5-point Likert scale to rate each item from 0 (no problem) to 4 (very severe problem).

Secondary Outcomes

  • Insomnia Severity Index (ISI)(6 months after randomization)
  • Patient Health Questionnaire (PHQ-9)(3 months and 6 months after randomization)
  • Responder Rate on Insomnia Severity Index(3 months after randomization)
  • Remission Rate on Insomnia Severity Index(3 months after randomization)
  • Generalized Anxiety Disorder Assessment (GAD-7)(3 months and 6 months after randomization)
  • Work and Social Assessment Scale (WSAS)(3 months and 6 months after randomization)

Study Sites (1)

Loading locations...

Similar Trials